Who are the real high-risk patients with pathological T2N0M0 non-small-cell lung cancer that can benefit from adjuvant chemotherapy?

ESMO Open

article

X. Hou¹  M.-Z. Yang²  J.-B. Li²  Z.-H. Tan¹  H. Long²  J.-H. Fu²  L.-J. Zhang²  P. Lin²  H.-X. Yang² 

[1] Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou City, Guangdong Province;State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou City, Guangdong Province;Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, Guangzhou City, Guangdong Province;Department of Clinical Research, Sun Yat-sen University Cancer Center, Guangzhou City, Guangdong Province

关键词: non-small cell lung cancer;    T2N0M0;    adjuvant chemotherapy;    survival;   

DOI  :  10.1016/j.esmoop.2022.100508

学科分类：社会科学、人文和艺术（综合）

来源: BMJ Publishing Group

【 摘 要 】

Background The benefit of adjuvant chemotherapy (ACT) in pathological T2N0M0 non-small-cell lung cancer (NSCLC) patients is not clear.Methods One thousand and fifty pathological T2N0M0 NSCLC patients were included and divided into two groups: with and without ACT. A propensity score matching analysis was carried out to minimize selection bias. The significance of ACT in high-risk patients was further analyzed. The Kaplan–Meier method and Cox proportional hazards model were used to assess the impact of ACT on the overall survival (OS), disease-free survival (DFS), and cancer-specific survival.Results For the entire cohort, 31.9% (335/1050) of patients received ACT. After propensity score matching, 325 pairs of patients were matched. OS and DFS were comparable between groups in the original or matched cohort, which was confirmed by the multivariate analysis (all P4 cm (OS: P = 0.003; DFS: P = 0.013). ACT could significantly improve the 5-year OS in patients with wild-type epidermal growth factor receptor (EGFR) (P4 cm or wild-type EGFR (all P 0.05). For patients with other high-risk factors, ACT failed to benefit patients in long-term outcomes.Conclusions 4 cm and wild-type EGFR are real high-risk patients and could gain survival benefit from ACT. Further prospective study is needed to confirm the definition.

【 授权许可】

CC BY|CC BY-NC-ND